Filter By Category
Archives
Share on -
ATINVICITINIB
Generic Name: ATINVICITINIB
ABSTRACT -
Atinvicitinib is a selective Janus kinase 1 (JAK1) inhibitor developed as a veterinary medicinal product for control of pruritus associated with allergic dermatitis in dogs. It is a small-molecule pyrazole carboxamide derivative with molecular formula C16H17FN6O3.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE -
- Dosage must be prescribed by a licensed veterinarian.
- Administer only to dogs that meet label criteria for age, body weight, and diagnosis.
- Do not adjust dose without veterinary guidance.
- Periodic recheck and monitoring may be required for chronic allergic skin disease.
SIDE EFFECTS–
Possible side effects and safety concerns include:
- Vomiting, diarrhea, reduced appetite, or lethargy
- Skin or ear infections may occur in susceptible dogs
- Changes in blood counts or clinical chemistry may require monitoring
- Excessive thirst, behavioral changes, or worsening skin disease should be reported
- Allergic reactions are possible with any medicinal product.
ALLERGIC REACTIONS -
Hypersensitivity to Atinvicitinib or related compounds/products may occur. Symptoms may include:
- Immediate urticaria or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing or breathing difficulty
- Dizziness, collapse, or anaphylaxis
Important: Patients who develop an allergic reaction to Atinvicitinib should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Atinvicitinib may interact with certain medicines, protocols, vaccines, clinical conditions, or procedures. Caution is needed with:
- Other immunomodulators, corticosteroids, or biologics may increase immune-suppression risk.
- Vaccination timing should be reviewed by the veterinarian.
- Concurrent antimicrobials or antifungals should be used only when clinically indicated.
- Do not combine with other JAK inhibitors unless specifically directed.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Use only after veterinary diagnosis of allergic dermatitis or atopic dermatitis.
- Screen for infections, demodicosis, neoplasia risk, or other causes of itching as appropriate.
- Use caution in breeding, pregnant, or lactating animals unless label supports use.
- Owners should report persistent vomiting, lethargy, infection, or worsening lesions.
WARNINGS –
- Veterinary use only; not for human use.
- Keep tablets secured away from children and other animals.
- Do not use in dogs outside approved age or weight limits unless directed by a veterinarian.
- Seek urgent veterinary care for facial swelling, collapse, or severe reaction.
Share on -
. Developed by